Q1 2024 Generic Launches

Camber Pharmaceuticals is delighted to announce the successful launch of 14 new generic drugs in the first quarter of this year, bringing vital medications to patients faster. This accomplishment, with nearly one new product introduced each week, reflects the exceptional collaboration between R&D, Regulatory, Quality Control, Supply Chain, Customer Service, and other internal teams. You can see the recently launched products below.
- Oxcarbazepine Oral Suspension (Trileptal®)
- Atorvastatin Tablets (Lipitor®)
- Varenicline Tablets (Chantix®)
- Levonorgestrel & Ethinyl Estradiol Tablets (Alesse®)
- Theophylline ER Tablets (Theophylline®)
- Paliperidone ER Tablets (Invega®)
- Icosapent Ethyl Capsules (Vascepa®)
- Allopurinol Tablets (Zyloprim®)
- Quetiapine Fumarate Tablets (Seroquel®)
- Gabapentin Tablets (Gralise®)
- Aripiprazole Oral Solution (Abilify®)
- Pantoprazole Sodium DR Oral Suspension (Protonix®)
- Rufinamide Oral Suspension (Banzel®)
- Fesoterodine Tablets (Toviaz®)
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection